Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.


This page contains information on ReproCyc PRRS-PLE for veterinary use.
The information provided typically includes the following:
  • ReproCyc PRRS-PLE Indications
  • Warnings and cautions for ReproCyc PRRS-PLE
  • Direction and dosage information for ReproCyc PRRS-PLE


This treatment applies to the following species:
Manufacturer: Boehringer Ingelheim

Porcine Reproductive and Respiratory Syndrome-Parvovirus Vaccine

Reproductive Form,

Modified Live and Killed Virus

Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin

Read entire insert before use.

Read the product label before use.

For new or additional information on the latest in PRRS research and to answer questions, contact Boehringer Ingelheim Vetmedica Professional Services toll free at 1-800-325-9167.

ReproCyc PRRS-PLE Indications

For vaccination of healthy, susceptible sows and gilts as an aid in the reduction of disease associated with Porcine Reproductive and Respiratory Syndrome Virus, reproductive form, and as an aid in the prevention of disease caused by porcine parvovirus, Erysipelothrix rhusiopathiae and Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona.

Recommended for use in healthy, susceptible swine in PRRS virus positive herds only, per label directions.


Administration & Dosage: Rehydrate the vaccine by adding the full contents of the accompanying diluent to the vaccine vial. Shake well and use immediately. Rehydrate only with the bacterin diluent provided; do not mix with other materials. Other diluents may be virucidal.

Using aseptic technique, administer a single 5 mL dose intramuscularly to gilts and sows 4-6 weeks prior to breeding. Revaccinate with ReproCyc®-PLE in 3 to 4 weeks. Revaccinate with a single dose prior to each subsequent breeding.

Administer only to healthy gilts and sows in PRRS virus positive herds, and only by intramuscular injection. Administer the complete 5 mL dose to each gilt and sow vaccinated. Efficacy and safety of the vaccine at other than the dose or route prescribed on the label is unknown, and therefore not recommended and not USDA approved.

Anaphylactoid reactions may occur.


Administer epinephrine.

Storage Before Use

Store out of sunlight in the outer carton. Store at a temperature between 35-45°F (2-7°C). Do not freeze. Use entire contents when first opened. Do not use bottles of damaged product. Do not store reconstituted vaccine.

Withdrawal Period

Vaccinated sows and gilts are not to be harvested for human consumption before 21 days after vaccination.

Breeding Animals

Do not vaccinate pregnant sows or gilts, or boars of breeding age.


After use, burn containers and all unused contents by a procedure allowed by local, state, and federal regulations.

Expiration Date

Consult the outer carton for the last date this package of vaccine is acceptable for use.


For veterinary use only. For use only in gilts and sows in PRRS virus positive herds as directed.

If human exposure occurs, administer first aid and consult physician immediately.

Many factors must be considered in determining a sound PRRS vaccination program for a particular farm. To be most effective, the vaccine must be administered properly to healthy animals maintained in a proper environment under good management. Stressed or immunosuppressed gilts and sows should not be vaccinated as the efficacy of the vaccine in these animals is unknown. The level of individual animal and herd immunity required will vary with management practices, the degree of exposure to PRRS virus, and the level of susceptibility of each animal. The benefits and risks from vaccination will vary in part with the levels of PRRS virus in the herd, and the need for the herd or individual animals to maintain a particular status for virus isolation, serological, or other diagnostic tests. Therefore, the vaccination program must be carefully planned and implemented in collaboration with the herd veterinarian following label and insert indications and precautions.

Previous Or Active Prrs Virus Or Other Infection

The effect of concurrent or previous infections at or around the time of vaccination on the efficacy of this vaccine in reducing or modifying PRRS virus disease in gilts and sows is not known.

Shedding And Transmission Of Vaccine Virus By Vaccinates

Vaccine virus may be shed and transmitted to other populations of swine which are in contact with vaccinated swine. The duration of potential vaccine virus transmission may vary.

Research (Gorcyca et al., unpublished) indicates that vaccine virus is found at varying times post vaccination at locations (tonsil, nasal mucosa, urine, feces) from which the potential for shedding exists. The chances of vaccine virus shedding may be increased when animals are treated with glucocorticoids, and possibly by disease or environmental conditions which stress pigs and elevate levels of endogenous glucocorticoids.

One field study (Torrison, 1996) indicated that non-vaccinated pigs in contact with vaccinated pigs may seroconvert to vaccine virus. Use of the vaccine on farms or transport of pigs from the farms where vaccine has been used to farms wanting to remain PRRS virus seronegative is contraindicated.

Breeding Animals

Do not vaccinate pregnant sows or gilts, or boars of breeding age.

Vaccination during the latter part of gestation of pregnant sows or gilts, either intramuscularly (Gorcyca et al., 1995) or oronasally (Mengeling et al., 1995), which are PRRS virus naive and previously unvaccinated can result in piglets born vaccine viremic. The impact of vaccine viremia in the newborn pig is not known.

Vaccination of PRRS negative herds prior to breeding may result in a transient reduction of reproductive performance.

Vaccination of adult boars may result in the shedding of vaccine virus in the semen (Molitor, et al., 1995; Neilsen et al., 1995; Christoper-Hennings et al., 1995). Because the impact of shedding is not known, do not use in boars.

This vaccine is not USDA licensed for use in pregnant swine or boars of breeding age.

How Supplied

ReproCyc® PRRS-PLE is supplied in 20 dose cartons containing the lyophilized modified live virus in amber glass vials together with either 100 mL of diluent in plastic vials.


Amphotericin B, gentamicin, neomycin and thimerosal.

Reference literature cited is available from Boehringer Ingelheim Vetmedica, Inc.

Call Boehringer Ingelheim Vetmedica, Inc., Customer Service toll free at 1-800-325-9167 with any questions.

ReproCyc® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH.

© 2012 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.

Manufactured by: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506

Phone: 800-325-9167

U.S. Veterinary License No. 124


20 Doses, Rehydrate with 100 mL

This package contains one 20 dose vial of modified live virus vaccine and one 20 dose (100 mL) vial of killed virus-bacterin diluent.


NAC No.: 1028098.4

Telephone:   800-325-9167
Fax:   816-236-2717
Every effort has been made to ensure the accuracy of the ReproCyc PRRS-PLE information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-05-30